The Effect of Activated Factor VII for Intracerebral Hemorrhage Beyond 3 Hours Versus Within 3 hours

Completed

Phase N/A Results

Summary of Purpose

To compare ICH patients receiving Recombant Factor VII alpha(rFVIIa) beyond 3 to 4 hours from symptom onset with those treated 0 to 3 hours and control patients receiving standard treatment.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 14 January 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Novo Nordisk

Trial Design

Randomized clinical trial based on time from symptom onset.

Contacts

Not available